PRGO:NYE-Perrigo Company plc (USD)

EQUITY | Drug Manufacturers - Specialty & Generic | New York Stock Exchange

Last Closing

USD 24.95

Change

-0.37 (-1.46)%

Market Cap

USD 12.59B

Volume

1.41M

Analyst Target

USD 57.88
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Perrigo Co PLC develops, manufactures and distributes over-the-counter and generic prescription pharmaceuticals, nutritional products and active pharmaceutical ingredients.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-07 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
ZTS Zoetis Inc

-2.41 (-1.45%)

USD 74.37B
HLN Haleon plc

+0.01 (+0.11%)

USD 44.13B
TAK Takeda Pharmaceutical Co Ltd A..

+0.05 (+0.38%)

USD 42.24B
RDY Dr. Reddy’s Laboratories Ltd..

+0.25 (+1.62%)

USD 13.11B
CTLT Catalent Inc

N/A

USD 11.52B
ELAN Elanco Animal Health

-0.12 (-1.01%)

USD 5.75B
AMRX Amneal Pharmaceuticals, Inc. C..

+0.10 (+1.29%)

USD 3.59B
BHC Bausch Health Companies Inc

+0.05 (+0.64%)

USD 2.75B
CPHI China Pharma Holdings Inc

-0.03 (-10.38%)

USD 3.69M
YCBD cbdMD Inc

-0.06 (-10.59%)

USD 1.96M

ETFs Containing PRGO

FLWR:SW 15.27 % 0.00 %

N/A

N/A
HLIT:CA Global X Lithium Producer.. 8.14 % 0.00 %

-0.07 (-0.06%)

CAD 0.01B
ION Proshares S&P Global Core.. 3.79 % 0.00 %

-0.02 (-0.06%)

USD 2.54M
GNRX 0.00 % 0.55 %

N/A

N/A
PILL Direxion Daily Pharmaceut.. 0.00 % 0.98 %

+0.12 (+-0.06%)

N/A
XPH SPDR® S&P Pharmaceutical.. 0.00 % 0.35 %

+0.25 (+-0.06%)

N/A
ISRL:LSE 0.00 % 0.00 %

N/A

N/A
TASE:LSE 0.00 % 0.00 %

N/A

N/A
QDVM:F 0.00 % 0.00 %

N/A

N/A
QDVM:XETRA 0.00 % 0.00 %

N/A

N/A
WSRD:CA Wealthsimple Developed Ma.. 0.00 % 0.00 %

-0.17 (-0.06%)

CAD 0.72B
FLWG:LSE 0.00 % 0.00 %

N/A

N/A
FLWR:LSE 0.00 % 0.00 %

N/A

N/A
BLUM:XETRA 0.00 % 0.00 %

N/A

N/A
BLUM:F 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -2.96% 14% F 9% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return -2.96% 14% F 9% A-
Trailing 12 Months  
Capital Gain -26.34% 20% F 8% B-
Dividend Return 3.26% 50% F 48% F
Total Return -23.08% 27% F 8% B-
Trailing 5 Years  
Capital Gain -49.89% 43% F 10% F
Dividend Return 10.23% 40% F 32% F
Total Return -39.65% 43% F 10% F
Average Annual (5 Year Horizon)  
Capital Gain -13.08% 13% F 4% F
Dividend Return -10.68% 13% F 4% F
Total Return 2.40% 83% B 55% F
Risk Return Profile  
Volatility (Standard Deviation) 8.13% 100% F 84% B
Risk Adjusted Return -131.36% 7% C- N/A F
Market Capitalization 12.59B N/A N/A N/A N/A

Key Financial Ratios

  Ratio vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Ratio vs. Market (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A
Price/Book Ratio N/A N/A N/A
Price / Cash Flow Ratio N/A N/A N/A
Price/Free Cash Flow Ratio N/A N/A N/A
Management Effectiveness  
Return on Equity N/A N/A N/A
Return on Invested Capital N/A N/A N/A
Return on Assets N/A N/A N/A
Debt to Equity Ratio N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector